BR112017006593A2 - método para detectar câncer de ovário - Google Patents

método para detectar câncer de ovário

Info

Publication number
BR112017006593A2
BR112017006593A2 BR112017006593A BR112017006593A BR112017006593A2 BR 112017006593 A2 BR112017006593 A2 BR 112017006593A2 BR 112017006593 A BR112017006593 A BR 112017006593A BR 112017006593 A BR112017006593 A BR 112017006593A BR 112017006593 A2 BR112017006593 A2 BR 112017006593A2
Authority
BR
Brazil
Prior art keywords
ovarian cancer
detect ovarian
detect
prognosis
disease
Prior art date
Application number
BR112017006593A
Other languages
English (en)
Inventor
Hilvo Mika
Original Assignee
Zora Biosciences Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zora Biosciences Oy filed Critical Zora Biosciences Oy
Publication of BR112017006593A2 publication Critical patent/BR112017006593A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/64—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving ketones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Abstract

a presente invenção refere-se ao campo do diagnóstico de câncer de ovário. a invenção introduz novos marcadores que podem ser utilizados para detectar a presença de câncer de ovário e fornecer um prognóstico da doença.
BR112017006593A 2014-10-02 2015-10-02 método para detectar câncer de ovário BR112017006593A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20145855 2014-10-02
PCT/FI2015/050654 WO2016051020A1 (en) 2014-10-02 2015-10-02 Methods for detecting ovarian cancer

Publications (1)

Publication Number Publication Date
BR112017006593A2 true BR112017006593A2 (pt) 2017-12-19

Family

ID=55629471

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017006593A BR112017006593A2 (pt) 2014-10-02 2015-10-02 método para detectar câncer de ovário

Country Status (10)

Country Link
US (1) US10534001B2 (pt)
EP (1) EP3201623B1 (pt)
JP (1) JP6892820B2 (pt)
KR (1) KR20170061704A (pt)
CN (1) CN106716127B (pt)
AU (1) AU2015326756A1 (pt)
BR (1) BR112017006593A2 (pt)
CA (1) CA2959832A1 (pt)
SG (1) SG11201701875YA (pt)
WO (1) WO2016051020A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351938A1 (en) * 2017-01-18 2018-07-25 BIOCRATES Life Sciences AG New biomarkers for assessing ovarian cancer
US20210405054A1 (en) 2017-07-05 2021-12-30 Zora Biosciences Oy Methods for detecting ovarian cancer
CN107656006A (zh) * 2017-09-08 2018-02-02 上海市东方医院 用于检测血清或者血浆中α‑羟基丁酸浓度的试剂盒和方法
CN108152430A (zh) * 2017-12-21 2018-06-12 上海中科新生命生物科技有限公司 基于prm检测的卵巢癌标志物检测试剂盒及检测方法
CN111430030A (zh) * 2020-04-17 2020-07-17 武汉大学 生物标志物在卵巢癌评估中的应用方法及系统
CN114544848B (zh) * 2020-11-25 2023-04-28 中国科学院大连化学物理研究所 一种用于诊断卵巢上皮癌的血清脂质标志物组合物及试剂盒和其与应用
EP4246146A1 (en) * 2022-03-14 2023-09-20 Fundació Institut Mar d'Investigacions Mèdiques (IMIM) Method for diagnosing cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824555A (en) 1996-05-30 1998-10-20 The Cleveland Clinic Foundation Method of detecting gynecological carcinomas
US20050054942A1 (en) * 2002-01-22 2005-03-10 Melker Richard J. System and method for therapeutic drug monitoring
US20030180953A1 (en) * 2000-12-29 2003-09-25 Elitra Pharmaceuticals, Inc. Gene disruption methodologies for drug target discovery
WO2003015436A1 (de) * 2001-08-10 2003-02-20 Siemens Aktiengesellschaft Verfahren zum schnellen und lokalen fehlerbeheben beim ausfall einzelner physikalischer verbindungen in gebündelten kommunikationsverbindungen und kommunikationssystem-vorrichtung zum durchführen des verfahrens
US20040180387A1 (en) * 2003-03-13 2004-09-16 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
US20050170441A1 (en) 2003-09-12 2005-08-04 Health Research, Inc. Early detection of cancer of specific type using 1HNMR metabonomics
WO2009052186A1 (en) 2007-10-15 2009-04-23 Georgia Tech Research Corporation Metabolomics-based identification of disease-causing agents
US8039668B2 (en) * 2008-10-17 2011-10-18 Burnham Institute For Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
GB2469244A (en) 2008-01-28 2010-10-06 Univ Singapore Lipid tumour profile
US20120004854A1 (en) 2008-05-28 2012-01-05 Georgia Tech Research Corporation Metabolic biomarkers for ovarian cancer and methods of use thereof
JP4744618B2 (ja) * 2009-04-13 2011-08-10 シャープ株式会社 ガス成分検出装置
US20120197539A1 (en) * 2009-10-09 2012-08-02 Carolyn Slupsky Methods for diagnosis, treatment and monitoring of patient health using metabolomics
US20110114511A1 (en) * 2009-11-17 2011-05-19 Sjong Angele Apparatus for detecting volatile organic compounds and related methods
GB201016139D0 (en) 2010-09-24 2010-11-10 Univ Leuven Kath Cancer phosholipidome
FI20115576A0 (fi) * 2011-06-10 2011-06-10 Teknologian Tutkimuskeskus Vtt Oy Menetelmä Alzheimerin taudin diagnoimiseksi
US20140156573A1 (en) 2011-07-27 2014-06-05 The Research Foundation Of State University Of New York Methods for generating predictive models for epithelial ovarian cancer and methods for identifying eoc

Also Published As

Publication number Publication date
CA2959832A1 (en) 2016-04-07
EP3201623A1 (en) 2017-08-09
US20170285036A1 (en) 2017-10-05
JP6892820B2 (ja) 2021-06-23
EP3201623A4 (en) 2018-07-25
US10534001B2 (en) 2020-01-14
JP2017535756A (ja) 2017-11-30
SG11201701875YA (en) 2017-04-27
AU2015326756A1 (en) 2017-05-11
EP3201623B1 (en) 2020-07-22
KR20170061704A (ko) 2017-06-05
WO2016051020A1 (en) 2016-04-07
CN106716127A (zh) 2017-05-24
CN106716127B (zh) 2020-12-08

Similar Documents

Publication Publication Date Title
BR112017006593A2 (pt) método para detectar câncer de ovário
CL2016001708A1 (es) Determinantes de respuesta del cáncer a la inmunoterapia
CL2016002455A1 (es) Anticuerpos multiespecíficos.
BR112017004802A2 (pt) anticorpos anti-cll-1 e imunoconjugados
ECSP17029371A (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
GT201700284A (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
GB2528044B (en) Non-touch optical detection of vital signs
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112016025627A2 (pt) biomarcadores e combinações dos mesmos para diagnóstico de tuberculose
CL2018001275A1 (es) Sistema de detección electroquímica de moléculas de interés
EP3140426A4 (en) Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma
BR112016022407A2 (pt) composições e métodos relacionados ao diagnóstico do câncer de próstata
BR112017013093A2 (pt) processos para a preparação de um composto de diariltio-hidantoína
BR112018002382A8 (pt) Novos anticorpos anti-gvpi humano e usos dos mesmos
BR112018013272A2 (pt) composições e métodos para detectar e tratar câncer esofágico
BR112017016562A2 (pt) métodos de produção de composições líquidas
CO2018007621A2 (es) Composiciones y métodos para evaluar el riesgo de ocurrencia de cáncer
MA40636A (fr) Procédés pour détecter le cancer de la prostate
BR112018013268A2 (pt) composições e métodos para detectar e tratar câncer gástrico
BR112017021850A2 (pt) detecção de isoformas específicas de clusterina
DK3132053T3 (da) Differentialdiagnose af eksem og psoriasis
BR112018013271A2 (pt) composições e métodos para detectar e tratar câncer de ovário

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements